Navigation Links
Access Licenses ProLindac(TM) and MuGard(TM) to JCOM Ltd, an Affiliate of DONG-A Pharmaceuticals in Korea
Date:2/19/2009

e funded by our external partners for ProLindac and will allow us to build a robust data package in a number of potential indications far beyond what we could generate on our own." Mr. Davis continued, "We are also extremely excited about having one of the largest Pharma companies in Korea promoting our MuGard product."

About ProLindac(TM):

ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion. Access recently presented data from the ongoing Phase 2 monotherapy clinical study of ProLindac in patients with recurrent ovarian cancer. In two dosing regimens, ProLindac was given once every two weeks and once every three weeks. During the last and highest dose levels explored, sustained and significant reductions in the specific serum market Ca-125 were seen over multiple dosings in several patients. ProLindac was well-tolerated with minimal side-effects.

About MuGard(TM): MuGard is a ready-to-use mucoadhesive oral wound rinse. The mucoadhesive formulation forms a protective coating over the oral mucosa when washed around the mouth. In a comparison of cancer patients receiving standard mucositis care with those patients using MuGard, the incidence and severity of mucositis was significantly lower in the MuGard treated group. Up to 40% of all patients receiving chemotherapy and/or radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
10. Childrens Hospital Cancer Study Finds Adolescents and Young Adults Dont Get Same Access to Cutting-Edge Treatment as Younger Patients
11. Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 InVivo Therapeutics Holdings Corp. (OTCQB: ... is revolutionizing spinal cord injury (SCI) treatment with their ... outperform in tissue regrowth in the spinal cord area ... an FDA approved polymer, the scaffold ultimately breaks down ... the human body. NVIV has recently attracted significant investor ...
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, ... Online, complimentary registration available at: http://bit.ly/1yStiU9 ... Archana Vidyasekar and Visionary Innovation Research Group ... wireless electricity, self-assembling materials, nanobots and flexible ... which will transform our lives in the ...
(Date:10/22/2014)... YORK , Oct. 22, 2014 Provectus ... dermatology therapies. PV-10, its novel investigational drug for cancer, ... potential for systemic side effects. Its oncology focus is ... Provectus has completed phase 2 trials of PV-10 as ... a topical treatment for atopic dermatitis and psoriasis. ...
Breaking Medicine Technology:InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... , BETHESDA, Md., Dec. 4 Northwest Biotherapeutics, Inc. ... that the US Patent and Trademark Office has allowed its ... stages of the manufacture of the Company,s DCVax® therapeutic cancer ... very high concentration of dendritic cells (which are the critical ...
... , RARITAN, N.J., Dec. 4 Depression, anxiety ... disorder and migraine: These are among the comorbidities reported ... had been diagnosed with epilepsy versus those without an ... households across the U.S. , Findings from " CNS-Related ...
Cached Medicine Technology:Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 2Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 3Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 4Northwest Biotherapeutics Receives Approval of US Patent for Cost Saving Automation of High-Concentration DCVax(R) Manufacturing 5Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 2Looking Ahead to AES 2009: New Insights on Comorbidities and Other Considerations for Epilepsy Treatment 3
(Date:10/22/2014)... TUESDAY, Oct. 21, 2014 (HealthDay News) -- The ... passengers arriving from Ebola-affected nations of West Africa ... screen them for infection with the virus. ... Jeh Johnson noted that 94 percent of air ... land at one of these five airports -- ...
(Date:10/22/2014)... 22, 2014 With the Affordable Care Act ... by the American Institutes for Research (AIR) finds that three ... use health insurance, but 42 percent say they are not ... before signing up for coverage. , The AIR survey found ... percent able to calculate correctly how much they owe for ...
(Date:10/22/2014)... 22, 2014 Losing Weight Your Body’s Way ... staring you in the face, it certainly can be difficult ... your body an extra favor by doing it the healthy ... diets. Instead, listen to your body, exercise regularly, and choose ... essential to losing weight; you need to exercise more and ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... among young adult men may lead to increased blood pressure, ... cause a similar rise in blood pressure for young adult ... when young adult women drank lightly or moderately, their risk ... found. "This finding parallels studies in older adult men ...
Breaking Medicine News(10 mins):Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4
... Harrisburg, PA-based national dental insurer United Concordia Companies, Inc. has renamed ... Claim, to better communicate the Web-based nature of the service.The online ... , Free electronic claims ... Real-time explanations of benefits (EOBs) , ...
... AGA Medical Corporation (AGA) today,announced that, following ... the German court of appeals over Occlutech GmbH,of ... Occlutech of the,amount of damages that it will ... learning that Occlutech has terminated all manufacturing and,sales ...
... Jan. 29 A national coalition of ... other,stakeholders, has been created to help breast ... prostheses and related post-surgical items. Known ... for the Advancement, Reform,and Equity), the coalition, ...
... Medical Spa Industry Expert and CEO of Acara Medspa Consulting Group, ... 20 MedSpa Professionals from across the nation joined him for this ... ... -- 20 Top MedSpa owners, operators and managers this week attended ...
... Columbia Doctors, the Physicians and Surgeons of Columbia University select ... to medical practices and healthcare clinics, as their transcription vendor ... record. , ... Scottsdale, AZ (PRWEB) ...
... - A New Year of Growth in 2008, ... - Higher Earnings Expected , ... revenue of EUR3,074.5 million for the year ended,December 31, 2008, representing ... growth for the year was a strong 9.7%. , ...
Cached Medicine News:Health News:Speed eClaim Helps National Dental Insurer United Concordia Process Claims Quickly, Efficiently and Electronically 2Health News:AGA Medical Corporation Begins Proceedings Against Occlutech to Recover Damages 2Health News:New Coalition Created to Help Breast Cancer Survivors Gain Access to Products Designed to Improve Their Quality of Life 2Health News:20 MedSpa Professionals Gain Insight into MedSpa Business Turnaround Tactics 2Health News:Columbia Doctors, the Physicians and Surgeons of Columbia University Select MxSecure, Inc., as Their Medical Transcription Vendor of Choice 2Health News:Essilor : 2008 Revenue 2Health News:Essilor : 2008 Revenue 3Health News:Essilor : 2008 Revenue 4Health News:Essilor : 2008 Revenue 5Health News:Essilor : 2008 Revenue 6
Disposable Microscissors: Horizontal Curved Microscissors...
Sharp tipped illuminated scissors with a curvature of 12 mm to follow the contour of the retina. For cutting in the plane parallel to the retina, cutting membranes adherent to the retinal surface and...
Disposable Microscissors: Vertical, 90...
Sharp tipped scissors with a curvature of 12 mm to follow the contour of the retina. For cutting in the plane parallel to the retina, cutting membranes adherent to the retinal surface and all purpose...
Medicine Products: